PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.

What this Trial Is About

This research investigates the causes and risks of pre-eclampsia in women who become pregnant after fertility treatments involving oocyte donation. The study compares two groups: women pregnant after oocyte donation and women pregnant after IVF using their own eggs. The study aims to understand immune and vascular factors involved in pre-eclampsia and to evaluate pregnancy and newborn outcomes in these women. Participants are followed throughout pregnancy with regular blood samples, blood pressure checks, clinical visits, and ultrasound exams. Early pregnancy visits include informed consent and baseline data collection. Follow-up visits occur at gestational weeks 12-14, 18-20, 28, 34, and 38, with blood samples and clinical assessments. Blood pressure is monitored weekly from week 28 until delivery. After birth, clinical outcomes such as delivery details and newborn health are recorded. Participants provide medical history and lifestyle information at enrollment. Researchers measure pre-eclampsia occurrence, biochemical markers, immune markers, and pregnancy complications. Data is collected securely, and participant confidentiality is maintained. The study includes postpartum monitoring and aims to establish a biobank for future research. Total participation spans from early pregnancy through delivery and postpartum data collection.

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)